The stock has a 36-month beta value of 1.45. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATAI is 137.08M, and at present, short sellers hold a 8.00% of that float. On July 01, 2025, the average trading volume of ATAI was 2.16M shares.
ATAI) stock’s latest price update
ATAI Life Sciences N.V (NASDAQ: ATAI)’s stock price has plunge by 18.04relation to previous closing price of 2.19. Nevertheless, the company has seen a 22.51% surge in its stock price over the last five trading sessions. benzinga.com reported 2025-07-01 that Atai Life Sciences ATAI and Beckley Psytech Limited jointly announced topline results from the eight-week, quadruple-masked, dose-finding core stage of the Phase 2b trial of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with treatment-resistant depression (TRD).
ATAI’s Market Performance
ATAI Life Sciences N.V (ATAI) has seen a 22.51% rise in stock performance for the week, with a 11.90% gain in the past month and a 90.07% surge in the past quarter. The volatility ratio for the week is 6.43%, and the volatility levels for the past 30 days are at 8.60% for ATAI. The simple moving average for the past 20 days is 13.41% for ATAI’s stock, with a 63.83% simple moving average for the past 200 days.
Analysts’ Opinion of ATAI
Many brokerage firms have already submitted their reports for ATAI stocks, with H.C. Wainwright repeating the rating for ATAI by listing it as a “Buy.” The predicted price for ATAI in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on November 18, 2024 of the previous year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see ATAI reach a price target of $6. The rating they have provided for ATAI stocks is “Buy” according to the report published on April 03rd, 2024.
Loop Capital gave a rating of “Buy” to ATAI, setting the target price at $18 in the report published on November 01st of the previous year.
ATAI Trading at 34.03% from the 50-Day Moving Average
After a stumble in the market that brought ATAI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.08% of loss for the given period.
Insider Trading
Kirpekar Sahil, the Chief Business Officer of ATAI Life Sciences N.V, sale 48,563 shares at $1.35 during a trade that took place back on Mar 21 ’25, which means that Kirpekar Sahil is holding 115,636 shares at $65,560 based on the most recent closing price.
Stock Fundamentals for ATAI
Current profitability levels for the company are sitting at:
- -53.12 for the present operating margin
- 0.88 for the gross margin
The net margin for ATAI Life Sciences N.V stands at -79.97. The total capital return value is set at -0.59. Equity return is now at value -62.43, with -50.86 for asset returns.
Based on ATAI Life Sciences N.V (ATAI), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -5.46. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -29.66.
Currently, EBITDA for the company is -145.33 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 258.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.07.
Conclusion
To sum up, ATAI Life Sciences N.V (ATAI) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
